Low dose ColchicinE in pAtients with peripheral Artery DiseasE to address residual vascular Risk (LEADER-PAD): A randomized trial (Vanguard Phase)

低剂量秋水仙素治疗外周动脉疾病患者以解决残余血管风险 (LEADER-PAD)：一项随机试验（先锋阶段）

• 批准号: 434730
• 负责人: Chan Noel
• 金额: $ 24.52万
• 依托单位: McMaster University
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2020
• 资助国家: 加拿大
• 起止时间: 2020-10-01 至 2023-04-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=434730&lang=en
• 关键词: Amputation; Anti Inflammatory; Atherosclerosis; Colchicine; Mortality; Myocardial Infarction; Peripheral Artery Disease; Randomized Controlled Trial; Revascularization; Stroke

Peripheral artery disease (PAD) is caused by fatty deposit build-up (atherosclerotic plaques) within an inflamed arterial wall that obstructs blood flow in leg arteries. The reduced blood flow to the legs can cause disabling leg pain and limit walking. Ot

外周动脉疾病(PAD)是由发炎的动脉壁内脂肪沉积(动脉粥样硬化斑块)导致的，它阻碍了腿部动脉的血液流动。流向腿部的血液减少会导致腿部疼痛，限制行走。奥特